Core Viewpoint - Ascentage Pharma-B (06855) shares rose nearly 4%, currently up 3.69% at HKD 53.4, with a trading volume of HKD 61.64 million [1] Group 1: Company Developments - On January 7, Ascentage Pharma announced via its official WeChat account that its novel BTK-targeted protein degrader APG-3288 has received IND approval from the US FDA, allowing the company to initiate clinical research for treating relapsed/refractory B-cell malignancies [1] - This marks a significant advancement in the company's research and development efforts in the field of targeted protein degradation, officially entering the clinical stage [1] - The study will be a global, multicenter, open-label Phase I clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies [1]

Core Viewpoint - The company, Ascentage Pharma-B (06855), has seen a nearly 4% increase in stock price following the announcement of FDA approval for its new drug application for APG-3288, a next-generation BTK-targeted protein degrader aimed at treating relapsed/refractory B-cell malignancies [1] Group 1: Company Developments - Ascentage Pharma announced that its innovative drug APG-3288 has received IND approval from the FDA, allowing it to proceed with clinical research [1] - The clinical study will be a global, multi-center, open-label Phase I trial focused on evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies [1] Group 2: Market Reaction - Following the announcement, Ascentage Pharma's stock price rose by 3.69%, reaching HKD 53.4, with a trading volume of HKD 61.64 million [1]

Group 1 - Dr. Debra Yu will be appointed as a new member of the Board Nomination Committee, effective from December 26, 2025 [1] - Dr. David Sidransky will be appointed as the Chief Independent Non-Executive Director, effective from December 26, 2025, to act as an intermediary between other directors and the company's shareholders, and to communicate with other directors and shareholders when normal communication channels with the Board Chairman or management are insufficient [1] - A Research and Development Committee will be established, effective from December 26, 2025, composed of scientists, doctors, and business experts to oversee R&D strategies, product lines, investments, and emerging trends while managing risks and ensuring alignment with business objectives [1] Group 2 - The R&D Committee will be chaired by Dr. Marc E. Lippman, with Dr. David Sidransky and Dr. Wang Shaomeng as members [1]

Core Viewpoint - Ascentage Pharma-B (06855) announced key appointments to its board, including the establishment of a new R&D committee, effective December 26, 2025 [1] Group 1: Board Appointments - Dr. Debra Yu will be appointed as a new member of the Board Nomination Committee, effective December 26, 2025 [1] - Dr. David Sidransky will be appointed as the Chief Independent Non-Executive Director, effective December 26, 2025, to act as an intermediary between other directors and the company's shareholders, and to communicate with other directors and shareholders when normal communication channels with the board chair or management are insufficient [1] Group 2: R&D Committee Establishment - The R&D Committee will be established, effective December 26, 2025, consisting of scientists, physicians, and business experts responsible for overseeing R&D strategies, product lines, investments, and emerging trends while managing risks and ensuring alignment with business objectives [1] - Dr. Marc E. Lippman will serve as the chair of the R&D Committee, with Dr. David Sidransky and Dr. Wang Shaomeng as members [1]

亞盛醫藥集團 ASCENTAGE PHARMA GROUP INTERNATIONAL 葉長青先生 任為先生 David Sidransky博士 （首席獨立非執行董事） Marina S. Bozilenko女士 Debra Yu博士 Marc E. Lippman, MD （於開曼群島註冊成立的有限公司） （股份代號：6855） 董事名單與其角色和職能 亞盛醫藥集團董事會（「董事會」）成員載列如下： 執行董事 楊大俊博士 （主席） 非執行董事 王少萌博士 呂大忠博士 獨立非執行董事 董事會設有三個委員會。各董事會委員會的組成載列如下： | | 董事委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | 研發委員會 | | --- | --- | --- | --- | --- | --- | | 董事 | | | | | | | 楊大俊博士 | | | | | | | 王少萌博士 | | | | | M | | 呂大忠博士 | | M | | | | | 葉長青先生 | | C | M | | | 1 | 董事委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | 研發委員會 | | --- | - ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的全部內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （於開曼群島註冊成立的有限公司） （股份代號：6855） 董事會欣然宣佈，David Sidransky博士將獲委任為首席獨立非執行董事（「首席獨 立非執行董事」），自2025年12月26日起生效，以(i)作為其他董事與本公司股東 之間的中間人；及(ii)在與董事會主席或本公司管理層的正常溝通渠道不足的情況 下，可與其他董事及本公司股東聯絡。首席獨立非執行董事並非本公司的行政職 位，且不擔任本集團的任何管理角色，亦不會承擔單獨或相較於其他獨立非執行 董事更高級別的責任或義務。 1 成立研發委員會 (1)提名委員會組成之變動； (2)委任首席獨立非執行董事； (3)成立研發委員會；及 (4)有關根據2022年受限制股份單位計劃進一步授出獎勵及 根據首次公開發售後購股權計劃授出購股權的補充公告 提名委員會組成之變動 亞 ...

Core Viewpoint - The "Annual Outstanding Biopharmaceutical Company" award was presented to Ascentage Pharma (06855.HK/AAPG.US) during the "Technology Empowerment · Capital Breakthrough" online sharing session held by Gelonghui on December 22 [1] Group 1 - The award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications in the biopharmaceutical field [1] - The evaluation criteria for the award include technological innovation, research and development strength, and the ability to translate results into practical applications [1]

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award was announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies were awarded, including Baillie Tianheng (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, listed in alphabetical order [1] Group 2: Evaluation Criteria - The evaluation for the award was based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were derived through quantitative data analysis and expert review [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award will be announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies, including Baillie Gifford (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, have been awarded the title [1] Group 2: Evaluation Criteria - The evaluation for the award is based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were determined through quantitative data analysis and an expert review panel [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Company Updates - The company announced that the global registration Phase III study POLARIS-1 for Narlik (Orelabrutinib) in 1L treatment of Ph+ ALL has received approval from the US FDA and European EMA [1] - The company will present multiple data sets for three products at the 2025 American Society of Hematology (ASH) annual meeting in December, including oral reports on domestic Phase II registration clinical data for Lisengrat (APG-2575) and the first readout of POLARIS-1 data [1] Clinical Data Highlights - POLARIS-1 has become the second global registration Phase III study for Narlik approved in Europe and the US, with preliminary data showing that as of July 18, 2025, 94.3% of 53 1L Ph+ ALL patients achieved CR/CRi within three months, with best MRD negative rates and MRD negative CR rates at 66.0% and 64.2% respectively [1] - Lisengrat demonstrated good efficacy in a high-risk population for R/R CLL/SLL, with an ORR of 62.5% and mPFS of 23.89 months as of July 25, 2025, with 21.8% achieving MRD negativity [2] - The combination of Lisengrat and Azacitidine in R/R AML/MPAL patients showed an ORR of 40.4% and CR of 29.8%, while in newly diagnosed high-risk MDS/CMML patients, the ORR was 80.0% [2] Financial Forecast and Valuation - The company maintains its net profit forecast for 2025 and 2026 at -1.09 billion and -0.30 billion respectively, and continues to outperform the industry model [2] - Based on DCF valuation, the target price is maintained at 89 HKD, indicating a potential upside of 56.3% from the current stock price [2]